Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

February 19th 2020

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

February 19th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Breaking Ground in GU Cancers

February 17th 2020

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Dr. Antonarakis on Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

February 15th 2020

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Vargas on Determining Role of SBRT Oligometastatic Prostate Cancer

February 15th 2020

Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.

ASCO GU 2020: Dr. Rini Highlights Key Research Efforts in Kidney Cancer

February 14th 2020

ASCO GU 2020: Dr. Petrylak Discusses Exciting Prostate Cancer and Bladder Cancer Data

February 14th 2020

ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer

February 14th 2020

ASCO GU 2020: Dr. Sonpavde Highlights Advancements in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Galsky Provides Insight on Potentially Practice-Changing Studies in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Albiges Recounts Exciting Research in RCC

February 14th 2020

OncLive News Network On Location: GU 2020 Day 3

February 14th 2020

OncLive News Network On Location: GU 2020 Day 2

February 14th 2020

OncLive News Network On Location: GU 2020 Day 1

February 14th 2020

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

February 14th 2020

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

February 14th 2020

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

3 Keys to Prostate Cancer Care: Clarify, Classify, Personalize

February 12th 2020

The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer

February 12th 2020

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

Enzalutamide Improves Survival in Nonmetastatic CRPC

February 12th 2020

Enzalutamide plus androgen deprivation therapy demonstrated a statistically significant improvement in overall survival compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer

February 8th 2020

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).